Coverage

Antitrust experts debate regulation to stop expensive drugs

Antitrust experts debate regulation to stop expensive drugs

04 March 2019

Despite higher drug prices in the US than in other nations, some antitrust observers doubt that government intervention is the answer to this problem.

FTC litigator: agency eyes REMS abuse as pay-for-delay wanes

FTC litigator: agency eyes REMS abuse as pay-for-delay wanes

01 March 2019

As fewer drugmakers cut reverse-payment deals, the Federal Trade Commission is keeping a close eye on pharmaceutical companies that abuse safety protocols to prevent competition, one of the agency’s top litigators has said.

Legislative mandate exists to address unfair prices in pharma sector, says EU enforcer

Legislative mandate exists to address unfair prices in pharma sector, says EU enforcer

28 February 2019

Despite the difficulty of pursuing excessive-pricing cases in the pharmaceuticals sector, the European Commission has a legislative mandate to go after such concerns, a director at the EU enforcer has said.

Chairs

J. Mark Gidley

White & Case, Washington, DC

J. Mark Gidley chairs the White & Case Global Antitrust/Competition practice, which is the only such practice to have been named Competition Group of the Year for seven years by Law360. His practice focuses on mergers and acquisitions, cartel cases, class actions, and pharmaceutical antitrust cases, with an emphasis on trying antitrust cases.

Christine Siegwarth Meyer

NERA Economic Consulting, New York

Featured as one of Global Competition Review's "Women in Antitrust," Dr. Christine Meyer is considered one of the foremost testifying economists in the areas of complex commercial litigation involving intellectual property, antitrust claims, and commercial damages. In the area of intellectual property, Dr. Meyer has analyzed damages and provided expert testimony concerning issues arising from patent, trademark, and copyright infringement, the misappropriation of trade secrets, and breaches of contract. She has considerable expertise in analyzing lost profits, reasonable royalties, price erosion, commercial success, and irreparable harm.

Keynote Speaker

Paul Csiszár

Director, Directorate General for Competition of the European Commission, Brussels

After graduating from ELTE School of Law of Budapest, Paul Csiszár studied international comparative law and earned a second Juris Doctorate at Loyola Law School in the United States. Following his admission to the Bar in 1986 in California he practiced as a corporate, securities and M&A lawyer in the US and then from 1997 in Central Europe with the international law firm of Squire Sanders until 2003 when he joined the public sector. Currently Mr Csiszár serves as Director of "Basic Industries, Manufacturing and Agriculture" at the Directorate General for Competition of the European Commission.

Speakers

Kathleen Bradish

Cleary Gottlieb Steen & Hamilton, Washington, DC

Mike Cowie

Dechert, Washington, DC

Thomas Dillickrath

Deputy Chief Trial Counsel, Federal Trade Commission, Virginia

David Emanuelson

Global Antitrust Counsel, Intel, Santa Clara

Kai-Uwe Kühn

Professor of Economics, University of East Anglia, Norwich

Edward Schwartz

Reed Smith, Washington, DC

Seth Silber

Wilson Sonsini Goodrich & Rosati, Washington, DC

Chris Stomberg

NERA Economic Consulting, Washington, DC

Programme

 8.45: Welcome coffee and registration

9.15: Chairs’ opening remarks

J. Mark Gidley, White & Case, Washington, DC
Christine Siegwarth Meyer, NERA Economic Consulting, New York 

9.30: Keynote address

Paul Csiszár, Director, Directorate General for Competition of the European Commission, Brussels

10.15: Pricing cases: what do they mean for the future of pharma?

The scrutiny of pricing in the pharmaceuticals sector has, if anything, become fiercer in 2018. How has this enforcement by the agencies and court decisions from private litigation affected the industry and its business practices?

Questions the panel are expected to discuss include:

  • What is the effect of industry consolidation on drug pricing?
  • How are the agencies evaluating the effect of mergers on short-term and longer-term pricing?
  • How has alleged collusion in the generic drugs market affected pricing, and how will those cases affect future enforcement?
  • How effective are “pay-for-delay” settlements in today’s industry?

Moderator:
Seth Silber, Wilson Sonsini Goodrich & Rosati, Washington, DC

Panel:
Thomas Dillickrath, Deputy Chief Trial Counsel, Federal Trade Commission, Virginia
Edward Schwartz, Reed Smith, Washington, DC
Chris Stomberg, NERA Economic Consulting, Washington, DC

11.30: Coffee break and welcome from Ken Reinker, Cleary Gottlieb Steen & Hamilton

12.00: Innovation: a double-edged sword?

Innovation is commonly accepted as beneficial for consumers and the market, but pharmaceutical companies have also been accused of using innovation and patents as an anti-competitive sword against potential competitors. How can companies understand what is ‘good’ and ‘bad’ innovation?

Questions the panel are expected to discuss include:

  • Is the pharmaceutical industry in need of more regulation - or less?
  • Is product hopping to extend patent life a clever tactic, or deleterious for the market?
  • How are method of use patents seen by authorities and courts?
  • What has been and will be the impact of alleged sham patent litigation?
  • How should innovation be considered in merger review in the pharma sector?

Moderator:
Kathleen Bradish, Cleary Gottlieb Steen & Hamilton, Washington, DC

Panel:
Mike Cowie, Dechert, Washington, DC
David Emanuelson, Global Antitrust Counsel, Intel, California
J. Mark Gidley, White & Case, Washington, DC
Kai-Uwe Kuhn, Professor of Economics, University of East Anglia, Norwich

13.15: Chairs’ closing remarks

J. Mark Gidley, White & Case, Washington, DC
Christine Siegwarth Meyer, NERA Economic Consulting, New York 

13.30: Networking lunch

14.30: Close of conference

Venue

2112 Pennsylvania Avenue, NW Washington, DC 20037

Ticket Prices

Private Practitioner
Type Price Until
Super Early $350 25 Jan 2019
Early $450 15 Feb  2019
Standard $550 28 Feb 2019

 

In-house/Government Representatives
Type Price
Standard $0